Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?
For patients with chronic-phase chronic myeloid leukemia (CML), a response-based dose-reduction strategy for ponatinib (Iclusig)…
Browsing Tag
ponatinib
Combination Therapy Achieves High Response in Ph+ ALL
A combination of ponatinib (Iclusig) and blinatumomab (Blincyto) achieved high rates of complete molecular remission and durable…